Navigation Links
Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting
Date:12/10/2013

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2013 /PRNewswire/ -- Calithera Biosciences, a biotechnology company focused on the development of novel cancer therapeutics, today announced the presentation of preclinical data for its lead anti-cancer therapeutic candidate, CB-839, at the 55th American Society of Hematology (ASH) Annual Meeting.  CB-839 is a potent, selective, orally available glutaminase inhibitor that interferes with tumor metabolism and blocks cancer cell growth and survival. 

"Glutaminase is an enzyme responsible for converting glutamine into a form that can be used by cells for energy production and the synthesis of macromolecules.  Many tumor types rely on glutamine for growth and survival, so with CB-839, we hope to block glutaminase activity and thereby starve the tumor of its energy source," said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera Biosciences.  "The data being presented at ASH demonstrate that CB-839 is a potent inhibitor of glutaminase and provide strong evidence for its potential therapeutic benefit in treating patients with hematologic malignancies.  We look forward to advancing CB-839 into Phase 1 studies in hematological patient populations early next year."

Calithera researchers evaluated the anti-tumor activity of CB-839 in diverse cell lines of B-cell malignancies including multiple myeloma, acute lymphocytic leukemia, and non-Hodgkin's lymphoma.  Treatment with CB-839 had anti-proliferative effects on the majority of tumor cell lines evaluated (36 out of 44) and induced cell death in a significant fraction of those cell lines.   In a xenograft model of multiple myeloma, oral twice-daily dosing of CB-839 resulted in a 70 percent inhibition of tumor growth.  Anti-tumor activity was dose dependent and was correlated with tumor glutamine accumulation, tumor glutamate decrease, and glutaminase inhibition.   Efficacious doses of CB-839 were well tolerated with no effects on hematologic cell counts or body weight.  The strong correlation between glutamine dependence and sensitivity to CB-839 in B cell tumor lines suggests that glutamine supports cell growth and survival in these tumors through metabolism of glutamine by glutaminase.  Calithera plans to advance CB-839 into Phase 1 clinical trials in patients with advanced solid and hematological tumors in early 2014.  

Calithera's in vitro and in vivo data on CB-839 were presented in a poster entitled, "Antitumor Activity of the Glutaminase Inhibitor CB-839 in Hematological Malignancies," (Abstract #4226), during the Chemical Biology and Experimental Therapeutics on December 9, 2013.

About Calithera Biosciences
Calithera is discovering and developing novel small molecule oncology therapeutics that inhibit pathways critical to tumor growth and survival.  The Calithera team has the experience and the ability needed to discover novel therapeutics and advance these discoveries through clinical development.  The company is applying this expertise to build a pipeline of anti-cancer compounds that are distinct from other oncology therapeutics.  Calithera's lead clinical candidate, CB-839, blocks glutaminase, an enzyme critical to tumor metabolism, and is poised to enter Phase 1 clinical testing.  Calithera Biosciences is a privately held company located in South San Francisco, CA.  For more information, please visit www.calithera.com.


'/>"/>
SOURCE Calithera Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
2. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
3. Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
4. Proove Biosciences CEO Brian Meshkin Wins 2013 Bridging the Gap Award by the Greater Baltimore Committee
5. Sangamo BioSciences Announces Presentation At The 25th Annual Piper Jaffray Healthcare Conference
6. Telomere Biosciences Announces: TELO-100 with T-Activator 150, a Breakthrough in Telomere Science and Age Management
7. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
8. Proove Biosciences Will Be Exhibiting at the National Workers Compensation Conference and Expo on November 20-22
9. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
10. Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimers Disease Program
11. Ambit Biosciences Announces Third Quarter 2013 Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Sciences today announced the three Winners and six Finalists of the 2017 Blavatnik ... annually by the Blavatnik Family Foundation and administered by the New York Academy ...
(Date:10/12/2017)... San Diego, CA (PRWEB) , ... ... ... BioInformatics (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform ... eliminating all bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, ...
(Date:10/11/2017)... BALTIMORE, Md. (PRWEB) , ... October 11, 2017 ... ... for digital pathology, announced today it will be hosting a Webinar titled, “Pathology ... of  Advanced Pathology Associates , on digital pathology adoption best practices and how ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):